- Latest week
- 10 Jul 2026
- Close
- 300.299988
- Fair value
- 201.633140
- Next-week expectancy
- Negative 25.01%
I1NC34 Chart Pack
Incyte Corporation
Chart Summary
Over the latest 12 completed weeks ending 2026-07-10, I1NC34 rose 27.16%, moving from 236.16 to 300.30. The latest weekly close is above the Trend Line and above Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 12 weeks. Relative Strength is 9.89 and has improved across the 12-week window. Market Dynamics is 0.90 on the latest week. Next-week expectancy is negative at 25.01% based on similar historical setup states.
Key Points
- Week Ending
- 10 Jul 2026
- Latest Close
- 300.30
- 12-Week Change
- 27.16%
- Trend Signal
- Inactive
- Next-Week Expectancy
- Negative 25.01%
- Signal Weeks
- 0 of 12
- Vs Trend Line
- Above
- Vs Fair Value
- Above
- Relative Strength
- 9.89
- Market Dynamics
- 0.90
Weekly Price
Price Action
Smart Money
Market Dynamics
Price Cycle
Next-State Map
SMI
Chart Summary
Key Points
- Week Ending
- 10 Jul 2026
- Latest Close
- 300.30
- 12-Week Change
- 27.16%
- Trend Signal
- Inactive
- Next-Week Expectancy
- Negative 25.01%
- Signal Weeks
- 0 of 12
- Vs Trend Line
- Above
- Vs Fair Value
- Above
- Relative Strength
- 9.89
- Market Dynamics
- 0.90
Over the latest 12 completed weeks ending 2026-07-10, I1NC34 rose 27.16%, moving from 236.16 to 300.30. The latest weekly close is above the Trend Line and above Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 12 weeks. Relative Strength is 9.89 and has improved across the 12-week window. Market Dynamics is 0.90 on the latest week. Next-week expectancy is negative at 25.01% based on similar historical setup states.
Industry Peers
Brazil equities in Biotechnology
| Stock | Exchange | Week | Open | High | Low | Close | Change |
|---|---|---|---|---|---|---|---|
| R2AR34 Ultragenyx Pharmaceutical Inc. | SAO | 10 Jul 2026 | 17.08 | 18.64 | 17.08 | 17.84 | 4.45% |
| REGN34 Regeneron Pharmaceuticals, Inc. | SAO | 10 Jul 2026 | 55.49 | 58.02 | 55.47 | 56.58 | 1.96% |
| B1ME34 BeOne Medicines AG | SAO | 10 Jul 2026 | 59.88 | 59.88 | 59.88 | 59.88 | 0.00% |
| B1MR34 BioMarin Pharmaceutical Inc. | SAO | 10 Jul 2026 | 142.02 | 142.02 | 142.02 | 142.02 | 0.00% |
| T1CH34 Bio-Techne Corporation | SAO | 10 Jul 2026 | 12.16 | 12.21 | 11.96 | 12.16 | 0.00% |
| BIOM3 Biomm S.A. | SAO | 10 Jul 2026 | 6.27 | 6.44 | 6.07 | 6.20 | -1.12% |
| S1RP34 Sarepta Therapeutics, Inc. | SAO | 10 Jul 2026 | 5.00 | 5.20 | 4.82 | 4.87 | -2.60% |
| B1NT34 BioNTech SE | SAO | 10 Jul 2026 | 30.30 | 30.90 | 29.34 | 29.34 | -3.17% |
| A1LN34 Alnylam Pharmaceuticals, Inc. | SAO | 10 Jul 2026 | 80.96 | 97.69 | 76.20 | 76.96 | -4.94% |
| A1RG34 argenx SE | SAO | 10 Jul 2026 | 191.03 | 191.03 | 180.31 | 180.31 | -5.61% |
| VRTX34 Vertex Pharmaceuticals Incorporated | SAO | 10 Jul 2026 | 680.26 | 682.26 | 621.33 | 621.43 | -8.65% |
| M1RN34 Moderna, Inc. | SAO | 10 Jul 2026 | 21.08 | 22.00 | 17.20 | 17.21 | -18.36% |